%0 Journal Article %A DAICHI FUJIMOTO %A RYOKO SHIMIZU %A RYOJI KATO %A YUKI SATO %A MARIKO KOGO %A JIRO ITO %A SHUNSUKE TERAOKA %A TAKEHIRO OTOSHI %A KAZUMA NAGATA %A ATSUSHI NAKAGAWA %A KOJIRO OTSUKA %A NOBUYUKI KATAKAMI %A KEISUKE TOMII %T Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease %D 2015 %J Anticancer Research %P 6261-6266 %V 35 %N 11 %X Background: The safety and efficacy of second-line chemotherapy for treating patients with small cell lung cancer (SCLC) and interstitial lung disease (ILD) have not been elucidated to date. Patients and Methods: Between January 2005 and September 2013, we analyzed 23 patients with SCLC and ILD who received second-line chemotherapy. Pre-existing ILD was diagnosed according to clinical features and pretreatment chest high-resolution computed tomography results. Results: The overall objective response rates and disease control rates were 22% and 52%, respectively. The median respective durations of progression-free survival and overall survival were 2.1 months (95% confidence interval (CI)=2.0-3.0 months) and 7.1 months (95% CI=3.6-11.3 months), respectively. Three patients with unusual interstitial pneumonia pattern (13%) developed chemotherapy-related pneumonitis. Conclusion: Second-line treatment may be an effective and safe option for SCLC patients with ILD after sufficient evaluation of risks and benefits. %U https://ar.iiarjournals.org/content/anticanres/35/11/6261.full.pdf